The UNMC College of Medicine received grant and funding awards representing $2,426,057 in new funding in April.
Steve Caplan, PhD, biochemistry and molecular biology, received a grant of $546,146 from DHHS/NIH/NIGMS for a study on mechanisms of membrane trafficking in endocytic and non-endocytic pathways.
Padmashri Ragunathan, PhD, neurological sciences, received a grant of $303,635 from Creighton University for the Traditional Hearing Center.
Ashley Deschamp, MD, pediatrics-pulmonary, received a grant of $105,230 from the Cystic Fibrosis Foundation for the Therapeutics Development Center.
Shaheed Merani, MD, PhD, surgery-transplant, received a grant of $100,000 from the American Society of Transplant Surgeons to study a strategy for improving post-transplant outcomes and donor organ utilization.
Karsten Bartels, MD, PhD, anesthesiology, received a grant of $89,466 from Columbia University for the Prime-Air Study – 1/2: An anesthesia-centered bundle to reduce postoperative pulmonary complications.
James Campbell, MD, internal medicine-general medicine, received a grant of $75,000 from the University of Colorado Denver for the National Center for Digital Health Informatics Innovation.
Christopher Conrady, MD, PhD, ophthalmology and visual sciences, received a grant of $70,000 from the Knights Templar Eye Foundation to study acute retinal necrosis in children.
Carol Toris, PhD, ophthalmology and visual sciences, received a grant of $63,062 from the Georgia Institute of Technology to study the development of a non-drug, non-surgical method to treat glaucoma. Dr. Toris also received funding for a T-Rex outflow facility assessment.
Carol Geary, PhD, pathology/microbiology, received a grant of $22,092 from the Task Force for Global Health for the Acute Flaccid Myelitis (AFM) Congenital and Perinatal Infections Rare Diseases Clinical Research Consortium. Dr. Geary also received a grant of $2,812 from the University of Kansas Medical Center Research Institute for collaborative research on privacy-preserving federated transfer learning for early acute kidney injury risk prediction.
Kari Simonsen, MD, pediatrics-infectious diseases, received a grant of $18,000 from the University of Alabama-Birmingham for the Data Coordinating and Operations Center (DCOC) for the IDeA States Pediatric Clinical Trials Network.
Hana Niebur, MD, pediatrics-allergy, received a grant of $15,300 from the University of Arkansas for Medical Sciences for the Data Coordinating and Operations Center (DCOC) for the IDeA States Pediatric Clinical Trials Network.
Shuai Li, MD, PhD, surgery-vascular surgery, received a grant of $15,300 from Central Social for Clinical and Translational Research to study the clinical significance and therapeutic potential of autophagy in peripheral artery disease.
Vijay Shivaswamy, MBBS, internal medicine-DEM, received a grant of $7,702 from the Nebraska Educational Biomedical Research Association as an ICA for Regan TeKolste.
Cyrus Desouza, MBBS, internal medicine-DEM, received a grant of $7,702 from the Nebraska Educational Biomedical Research Association as an ICA for Regan TeKolste.
Industry-sponsored grants and contracts:
The following industry-sponsored contracts and foundation grants were received.
Mara Seier, MD, neurological sciences, received funding for a study to assess the efficacy, safety and tolerability of Lu AF82422 in patients with Multiple System Atrophy.
Rao Chundury, MD, ophthalmology and visual sciences, received funding for a trial in patients with thyroid eye disease to evaluate the safety and tolerability of different dosing durations of teprotumumab.
Brad Brabec, MD, pediatrics-administration, received funding for a study to investigate orally administered PF-07321332 (nirmatrelvir)/ritonavir in nonhospitalized pediatric patients.
Krishna Gundabolu, MBBS, internal medicine-oncology/hematology, received funding for a protocol to determine potential patient eligibility for inclusion in AAV gene therapy clinical trials in haemophilia B.
Andrea Zimmer, MD, internal medicine-infectious diseases, received funding for a trial of viralym-m (ALVR105) for the treatment of patients with virus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplant.